Roundtable: ‘Appropriate Level’ Of Protection Is Key For Impact Of Patents In Health, Innovation 03/01/2017 by Peter Kenny for Intellectual Property Watch Leave a Comment One of the key questions around the impact of patents on health and innovation is what is the appropriate level of protection for companies innovating, says Dr. Marie-Paul Kieny, assistant director-general, Health Systems and Innovation, at the World Health Organization.
UN General Assembly Resolution: TRIPS Flexibilities, High-Level Panel On Medicines Access 16/12/2016 by William New, Intellectual Property Watch 1 Comment The United Nations General Assembly this month is considering a resolution committing to elevate health issues to the highest levels of foreign policy. The resolution includes references and commitments related to dozens of existing instruments and tools aimed at improving health, including a full range of those on access to medicines, such as patent flexibilities under trade rules, and the recent report of the UN Secretary-General’s High-Level Panel on access to medicines and innovation.
UNITAID Board Adopts Resolution On IP Flexibilities Under Trade Rules 16/12/2016 by Catherine Saez, Intellectual Property Watch 1 Comment The Executive Board of UNITAID yesterday adopted a resolution on the use of the intellectual property flexibilities enshrined in the global trading system allowing developing countries to facilitate access to affordable medicines.
Patents And Health Debate Brings Key WIPO Committee To Standstill 16/12/2016 by Catherine Saez, Intellectual Property Watch 1 Comment After a day spent in informal meetings to try to agree on what should be the future work of the World Intellectual Property Organization patent law committee, delegates had to admit defeat. The main point of contention, according to sources, was the request by developing countries that the committee work on the issue of patents and access to medicines, and address the recommendations of the United Nations Secretary-General’s High Level Panel on Access to Medicines. This request was met by blunt refusal by some developed countries as beyond the realm of the work of the committee.
Things Heat Up In WIPO Debate On Patents And Health 14/12/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization patent law committee this week became the latest venue for the global debate over the system to provide incentives to the pharmaceutical industry to find new medicines while ensuring all patients have access to those medicines. Most developing countries want the committee to discuss the recommendations of the United Nations Secretary-General’s High-Level Panel on Access to Medicines, while most developed countries disagree. The tone is rising, and the issue could come as a hurdle as countries decide the future work of the committee.
WIPO Patent Committee Asked To Discuss UN High Level Report On Access To Medicines 13/12/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization patent law committee is a unique international forum where discussions about the patent system are held. The committee meeting this week is a display of different views of developed and developing countries on how the patent system is expected to meet their needs.
US Supreme Court Declines To Hear Biologic Drug Patent Fight 13/12/2016 by Intellectual Property Watch Leave a Comment The US Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval before bringing them to the market.
UAEM Targets Accessible Medicines, R&D Financing, Publicly Funded Research 13/12/2016 by Alexandra Nightingale for Intellectual Property Watch 1 Comment From extracurricular creativity to global campaigns, Universities Allied for Essential Medicines (UAEM) continues in its activities to raise awareness and explore how universities can best direct their research and innovations towards promoting global access to medicines. In the next year, UAEM will extend its national and international campaigns to address the high prices of medicines, continue to gather support for a global agreement on research and development and build on the mapping alternative R&D initiatives.
A Look At The UNAIDS Board Debate On IP And Medicines; Outcome Fell Short For Some 12/12/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment The discussion on intellectual property-related barriers to access to medicines was one of the most contentious points of the 39th meeting of the UNAIDS governing board last week. After hours of negotiations, the board agreed that the organisation will keep working on the issue. But developing countries and civil society would have preferred a stronger mandate, according to representatives.
UNAIDS Board Carries Forward Multi-Agency Work On IP Barriers To Medicines Access 09/12/2016 by Catherine Saez, Intellectual Property Watch 1 Comment A meeting of the Board of the Joint United Nations Programme on HIV/AIDS (UNAIDS) has concluded with a set of decisions (attached) showing that the Board went farther than just noting the UNAIDS secretariat report on intellectual property-related barriers preventing access to medicines. And the Board, after lengthy discussions, also called on UNAIDS to facilitate discussions on the high-profile report of the United Nations Secretary-General’s High-Level Panel for Access to Medicines.